CYTOKINETICS INC Form 8-K February 02, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

February 2, 2012

Cytokinetics, Incorporated

(Exact name of registrant as specified in its charter)

000-50633

(Commission

File Number)

Delaware

(State or other jurisdiction of incorporation)

280 East Grand Avenue, South San Francisco, California

(Address of principal executive offices)

Registrant s telephone number, including area code:

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

94-3291317

(I.R.S. Employer Identification No.)

94080

(Zip Code)

(650) 624 - 3000

Edgar Filing: CYTOKINETICS INC - Form 8-K

<u>Top of the Form</u> Item 2.02 Results of Operations and Financial Condition.

On February 2, 2012, Cytokinetics, Incorporated issued a press release announcing its results for the fourth quarter ended December 31, 2011. A copy of the press release is being filed as Exhibit 99.1 to this Current Report and is hereby incorporated by reference into this item 2.02.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following Exhibit is filed as part of this Current Report on Form 8-K:

Exhibit No. Description

99.1 Press Release, dated February 2, 2012.

Edgar Filing: CYTOKINETICS INC - Form 8-K

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cytokinetics, Incorporated

February 2, 2012

By: /s/ Sharon Barbari

Name: Sharon Barbari Title: Executive Vice President, Finance and Chief Financial Officer

Edgar Filing: CYTOKINETICS INC - Form 8-K

Top of the Form

Exhibit Index

Exhibit No.	Description	

99.1

Press release, dated February 2, 2012